Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Research & Development (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Research & Development readings, the most recent being $23.7 million for Q4 2025.

  • On a quarterly basis, Research & Development fell 21.36% to $23.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $135.8 million, a 24.21% increase, with the full-year FY2025 number at $135.8 million, up 24.21% from a year prior.
  • Research & Development hit $23.7 million in Q4 2025 for Amicus Therapeutics, up from $23.4 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $85.6 million in Q4 2021 to a low of $23.4 million in Q3 2025.
  • Median Research & Development over the past 5 years was $41.1 million (2023), compared with a mean of $47.3 million.
  • Biggest five-year swings in Research & Development: tumbled 55.12% in 2023 and later surged 146.52% in 2025.
  • Amicus Therapeutics' Research & Development stood at $85.6 million in 2021, then dropped by 25.38% to $63.9 million in 2022, then crashed by 45.16% to $35.0 million in 2023, then dropped by 13.81% to $30.2 million in 2024, then dropped by 21.36% to $23.7 million in 2025.
  • The last three reported values for Research & Development were $23.7 million (Q4 2025), $23.4 million (Q3 2025), and $60.8 million (Q2 2025) per Business Quant data.